BOSTON – November 9, 2022 – General Electric Company (“GE”) (NYSE: GE) announced today that GE Healthcare Holding LLC (“GE HealthCare”), a direct, wholly-owned subsidiary of GE, priced an offering of $1,000,000,000 aggregate principal amount of 5.550% senior notes due 2024 (the “2024 notes”), $1,500,000,000 aggregate principal amount of 5.600% senior notes due 2025 (the... Read more
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO, IL and SUNNYVALE, Calif., – October 21, 2022: GE Healthcare and Accuray Incorporated (NASDAQ: ARAY) announced today that they have signed a global commercial collaboration agreement designed... Read more
Of the more than 500 devices included by the U.S. FDA on a recently updated list of AI-enabled device authorizations, 42 are from GE Healthcare, a milestone that highlights the impact of the company’s digital strategy. Chicago – October 20, 2022 – On a recently updated FDA list of artificial intelligence (AI) enabled medical devices,... Read more
Chicago and New York – October 19, 2022 – GE Healthcare and AMC Health today announced a collaboration that allows clinicians to offer Remote Patient Monitoring (RPM) as a virtual care solution that extends patient care outside the hospital to the home environment. The combination of GE Healthcare’s acute patient monitoring capabilities in the hospital... Read more
A partnership to foster Enterprise imaging and pathology for oncology The collaboration intends to bring a data management solution by interfacing Tribun’s Health Suite data into GE Healthcare’s products Buc, France – October 18, 2022 – GE Healthcare and Tribun Health have entered a collaboration with the intent to provide digital pathology departmental solutions that... Read more
New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection GE Healthcare’s Pharmaceutical Diagnostics business is an established global supplier of PET imaging tracers... Read more
Chicago, U.S. and Barcelona, Spain – October 16, 2022 – At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legend[i], the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO (dBGO) detector material with a small crystal size that delivers... Read more
Enables GE Healthcare to secure increasing supply of iodine, a key ingredient for contrast media products used in X-Ray and Computed Tomography (CT) imaging procedures Supports GE Healthcare’s broader commitment to address future demand for iodinated contrast media and deliver 30 million more patient doses annually by 2025 Investment plan also includes opening this week... Read more
Key milestone in GE HealthCare’s journey to becoming standalone public company leading precision health innovation; marks continued progress on GE’s plans to form three companies Creating innovative leader in healthcare with a powerful global franchise enabling more precise, connected, and compassionate care Positioned to meet a growing demand for medical technology solutions and serve an... Read more
Extending deep learning-based AIR Recon DL compatibility to 3D & PROPELLER has the potential to enable more confident patient diagnoses in MRI Chicago, US, September 29, 2022 – GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences[1]. The benefits of AIR Recon DL are extended... Read more